In a recent transaction, Jeffery Michael Craig, the General Counsel and Corporate Secretary of NeueHealth, Inc. (NYSE:NEUE), sold 260 shares of the company's common stock. The sale, dated March 18, 2024, totaled approximately $1,890, with the shares being sold at an average price of $7.27 each.
Investors might be interested to note that the shares were sold at prices ranging from $7.16 to $7.39 per share, as indicated by the weighted average price provided. This transaction was not made at Craig's discretion; it was carried out to cover tax withholding obligations related to the vesting of restricted stock units.
Following the sale, Craig still owns 3,426 shares of NeueHealth, indicating his continued investment in the company. The sale was reported in a regulatory filing with the Securities and Exchange Commission, which provides transparency into the transactions of company insiders.
As with all insider transactions, this sale provides investors with information about the actions of company executives, which can be a useful data point when assessing a company's stock for investment purposes.
InvestingPro Insights
NeueHealth, Inc. (NYSE:NEUE) has recently been in the spotlight due to insider activity, and current metrics from InvestingPro provide additional context for investors considering the company's financial health and stock performance. As of the latest data, NeueHealth's market capitalization stands at a modest $55.99 million. This relatively small market cap may reflect the company's current challenges as well as its potential for volatility.
Analyzing the company's profitability, the picture remains challenging. The Price/Earnings (P/E) Ratio, a key indicator of investor expectations of future earnings, is negative at -0.14 for the last twelve months as of Q4 2023, suggesting that the market does not anticipate earnings to outweigh the share price in the near term. This aligns with one of the InvestingPro Tips indicating that analysts do not expect the company to be profitable this year. Moreover, the company's revenue has seen a significant decline, with a -51.87% change over the last twelve months as of Q4 2023, reinforcing concerns about its sales trajectory.
Despite a strong return over the last three months, with a 34.65% price total return, the stock has experienced a substantial 1-year price total return of -68.52%, highlighting the high price volatility that investors have faced. This is consistent with another InvestingPro Tip, which suggests that the stock generally trades with high price volatility.
For investors looking for more comprehensive insights, there are additional InvestingPro Tips available that can help navigate the complexities of NeueHealth's financial landscape. With a total of 11 InvestingPro Tips, investors can further explore the company's cash burn rate, sales projections, and liquidity concerns, among other aspects. To access these insights and make more informed investment decisions, use the coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription at InvestingPro.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.